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Background: Participation in physical activity has been found to be beneficial for mental and physical health 
outcomes among cancer survivors. However, to date no intervention exists specifically to promote physical 
activity among bladder cancer survivors. In light of this knowledge a home-based exercise intervention was 
cocreated for those recently diagnosed with bladder cancer. 
Aim: The aim of the present study, financially supported by Action Bladder Cancer UK [1], is to pilot the 
homebased exercise intervention tailored specifically for bladder cancer survivors (i.e. from the point of 
diagnosis) to improve physical and mental health outcomes (during treatment and beyond) in this population. 
Methods: This study will use a randomised controlled trial design. Arm one will consists of the 14 week 
homebased exercise intervention and arm two usual care (15 participants will be randomised to each arm). 
Baseline data collection will take place shortly after clinical diagnosis of bladder cancer, and follow-up 
approximately 7 weeks and then again approximately 14 weeks after commencement of the intervention. At 
each data collection point data will be collected from participants relating to demographics, physical and 
mental health. Participants will aslo be asked to wear an Actigraph Accelerometer at each data collection 
point for seven consecutive days. Immediately after baseline data collection participants in the intervention 
arm will be given the home-based exercise booklet. 
 
Ethics and dissemination: Ethical approval was obtained for the present study via The London- City and East 
Research Ethics Committee (ID:291676). Results of this study will be disseminated through peer-reviewed 







Approximately, 10,000 people are diagnosed with bladder cancer every year and it's the tenth most common 
cancer in the UK. The condition is more common in older adults, with most new cases diagnosed in people 
aged 60 and above [2]. Importantly, the survival rate for bladder cancer (when compared to some other 
cancer types) is good. The general 5-year survival rate for people with bladder cancer is 77%, the overall 
10-year survival rate is 70% and the overall 15-year survival rate is 65% [3]. 
 
There are many common physical and psychological consequences of cancer and treatment, including 
fatigue, pain, sleep disturbance, lymphoedema, weight gain, loss of muscle mass, cancer-related distress 
(e.g. fear of recurrence, financial concerns), anxiety, and depression [4,5]. Furthermore, the majority of 
people living with and beyond cancer are living with at least one other long-term chronic condition (e.g. 
hypertension, obesity, mental health conditions) [6]. Treatment for bladder cancer often includes surgery 
(including Transurethral bladder tumour resection, Radical cystectomy and lymph node dissection, Urinary 
diversion [stoma]), but may also include chemotherapy, immunotherapy, and targeted therapy. These 
treatments result in specific unwanted side effects including for example, mild bleeding and discomfort after 
surgery, erectile dysfunction, loss of sexual feeling and orgasm, frequent urination, and those with advanced 
bladder cancer may have been fitted with a uro-stoma [7]. 
 
With a high bladder cancer survival rate and thus a relatively large proportion of people living with and beyond 
bladder cancer [8] it is important to consider health behaviour interventions to improve general health, 
bladder cancer-specific complications, and general quality of life. One such intervention may include the 
promotion of physical activity. Indeed, physical activity has been shown to reduce cancer-related fatigue, 
pain, maintain an adequate weight and muscle mass, reduce levels of distress, anxiety and depression, 
reduce the risk of erectile dysfunction, and aid in the prevention and maintenance of several other non-
communicable diseases [9–11]. In light of this knowledge The Independent Cancer Taskforce recommended 
that everyone diagnosed with cancer in the UK should have access to the elements of the Recovery Package 
by 2020. The Recovery Package is a series of key interventions which, when delivered together, can greatly 
improve outcomes for people living with and beyond cancer. The package includes an holistic needs 
assessment, treatment summary, cancer care review, health and wellbeing clinics. These elements are part 
of an overall support of self-management including physical activity as part of a healthy lifestyle, managing 
consequences of treatment, and information, financial and work support [12]. This was upheld in the recently 
published NHS Long Term Plan [13]. Physical activity, is highlighted in the Recovery Package due to 
evidence from randomized controlled trials (RCTs) of physical activity interventions that show improvements 
in fatigue, pain, sleep, lymphoedema, anxiety and depression, body composition and quality of life in people 
living with and beyond cancer [14]. Furthermore, there is a large body of observational evidence that shows 
 
that people living with and beyond cancer who are more active have reduced all-cause and cancer-specific 
mortality risk and a reduced risk of cancer recurrence [15]. 
 
However, despite the guidance levels of physical activity in cancer survivors are low. For example, in one 
study of US prostate cancer survivors objectively measured moderate-to-vigorous physical activity was low 
at all 4 time points (baseline, 5 week, 6 months and 12 months; median, 0.0–5.2 min/day), with no overall 
change across study assessments (global P = .29) [16]. Other studies in those living with and beyond other 
cancers have found similarly low levels of physical activity [17]. Therefore, interventions are urgently required 
to promote sustainable physical activity to those living with and beyond cancer. Moreover, to our knowledge 
to date no physical activity intervention has been developed and implemented specifically for those living 
with and beyond bladder cancer. Indeed, symptoms present in bladder cancer (differentiating from other 
solid tumour cancers) may further discourage individuals from participation in physical activity. Specifically, 
frequent urination and pain. Moreover, patients with advanced bladder cancer might also have a uro-stoma 
that can interfere with the perceived body image. 
 
Aim 
The aim of the present study, financially supported by Action Bladder Cancer UK1, is to pilot a home-based 
exercise intervention tailored specifically for bladder cancer survivors (i.e. from the point of diagnosis) to 
improve physical and mental health outcomes (during treatment and beyond) in this population. 
 
Setting 
King's Lynn is a hanseatic town on the coast of Norfolk in England. It has a population of approximately 
49,000 residents of whom approximately 50% are male and 59% are aged between 18 and 64 years with 
18% aged over 65 years. Moreover, approximately 95% of the population are white British [18]. The 
CADENCE Trial will be carried out initially in The Queen Elizabeth Hospital King's Lynn Foundation Trust 
NHS (QEHKL). Participants will be recruited from one oncology clinic at the hospital where patients are 
under the care of one urological consultant (co-principal investigator). The patients will be recruited from the 
patients with newly diagnosed bladder cancer or diagnosed with recurrence of bladder cancer at the QEHKL. 
They will subsequently be booked for a transurethral resection of the bladder cancer. About 20–30% of these 
patients will need further treatment in the form of radical cystectomy. 
 
Method and analyses 
The evaluation of this pilot study will use a randomised controlled trial design. Baseline data collection will 
take place shortly after clinical diagnosis of bladder cancer. The duration of the entire study will be 4–5 
months. Participants will be randomised by a trial coordinator (using simple random sampling) as they enter 
 
the study to either the control (usual care) or the intervention group (exercise) at baseline and prior to 
consent. Concealed allocation will take place. The unit of randomisation will be the participant. 
 
Recruitment 
Participants will be patients attending one urological consultant's oncology clinic or a flexible cystoscopy 
outpatient appointment and consecutively screened. If the patient meets the inclusion criteria the research 
team will provide them with a Participant Information Sheet and a Physical Activity Readiness Questionnaire 
at the point of clinical diagnosis. Approximately one week later the patient will be contacted by phone by 
either a trained research assistant or a member of the urological consultants care team. A one week window 
will be given to allow the patient time to read study material. The patient will be asked if they would like to 
take part in the study and if the Physical Activity Readiness Questionnaire deemed it okay for them to 
exercise (if exercise is not deemed acceptable the participant will not be recruited into the study). If the 
patient agrees to take part, an appointment will be made for them at QEHKL for consent and baseline data 
collection. Once recruited, patients will be randomised to usual care or exercise intervention. On arrival, for 
baseline data collection, and before any data is collected participants will be asked to provide written 
informed consent. Participants will be asked if they have any questions and will be told they can withdraw 
from the study at any point without giving reason and no adverse action will be taken as a result of this. 
 
Participants inclusion/exclusion criteria 
The study will be restricted to adults (age ≥18) who are able to consent for themselves (presumed from 
completion of the consent form) and individuals who receive a diagnosis of non-metastatic (stage I–III) 
bladder cancer. Patients will also be screened using the Physical Activity Readiness Questionnaire. Patients 
will be excluded if they are unable to provide informed consent due to severe cognitive impairment, and have 
metastatic disease (stage IV). 
 
Intervention 
A self-guided printed home-based exercise booklet has been cocreated for those with bladder cancer (see 
supplementary material). The content allows patients to achieve the World Cancer Research Foundations 
physical activity guidelines [1] being active every day for 30 min or more (and aiming for 10,000 steps a day) 
[2], getting stronger and fitter (doing strength, balance and stretching exercise twice per week and two 30 
min sessions of vigorous exercise per week) [19]. The booklet was co-created through an iterative process. 
First, the booklet was developed and designed by a sport scientist and a urological surgeon. Next, the 
content of the booklet was shared with patients, health professionals (urologists, oncology physiotherapist, 
and personal trainers) and experts (academics) in the field, who were asked to comment on the 
appropriateness of the content and make suggestions for improvement. The sport scientist and the urological 
 
surgeon then utilised this feedback to improve the booklet. This process continued until all involved were 
happy with its content. 
 
Control group 
All participants in the control group will complete all evaluation measures at each time point. Control 
participants will also be required to complete informed consent prior to collecting any measurements. 
 
Evaluation 
All evaluation measurements will be taken at baseline, approximately 7 weeks and then again approximately 
14 weeks after commencement of intervention (we say approximately as the timing depends on when the 
patients scheduled appoints occur). 
 
Measures 
After randomisation a trained research assistant will collect baseline data on participants demographic data 
including age, sex, education, current employment status, marital status and living arrangement (who they 
live with), and ethnicity by way of survey. Participants’ waist circumference (WC), height and weight (to 
calculate body mass index) will also be recorded. As well as body fat percentage and muscle mass using 
bio-impedance scales. Handgrip strength will be recorded using the handheld dynamometer. Fatigue will be 
assessed using the 13-item fatigue subscale of the Functional Assessment of Chronic Illness Therapy-
Fatigue (FACIT-F) questionnaire [20]. Sleep will be assessed using the Pittsburgh Sleep Quality Index [21], 
an 18-item questionnaire which assesses sleep quality and disturbances over a 1-month time interval. 
Quality of life will be assessed using the five-level EuroQol-5D questionnaire (EQ-5D-5L) [22]. Finally, 
participants will be fitted with the Actigraph accelerometer to measure free-living physical activity over 7 
consecutive days. Follow-up data will be collected at 7 weeks and 14 weeks. Patients randomised to the 
control comparator will receive ‘usual care’ and undergo all baseline and follow-up measures. 
 
Levels of free-living physical activity will be assessed using the Actigraph accelerometer (GT3X) at each 
data collection point. The Actigraph accelerometer is a valid and reliable tool to monitor free-living physical 
activity and its validity and reliability has been shown in multiple populations [23]. The Actigraph GT3X is 
worn on a belt around the waist with the device itself positioned above the right hip either over or under 
clothing. We will employ a sampling frequency of 30 Hz. Service users will be asked to wear the device 
during waking hours every day for seven consecutive days, but not during water-based activities or sleep. In 
addition to the above we will also collect data on the following variables: number of patients screened, 
proportion of patients enrolling, and number of patients who dropout of the study. 
 
 
Those in the intervention arm will also be asked to take part in one semi-structured qualitative interview. 
Interviews will explore experiences of the intervention including barriers and facilitators to compliance, 
satisfaction and perceived effectiveness of the different elements of the intervention, and suggestions for 
improvement. All interviews will be audio recorded and transcribed. With the consent of participants, semi-
structured interviews will be conducted. We anticipate that each interview will take approximately 30–45 min. 




The primary outcome for this study will be indicative change in average daily time spent in sedentary time, 
light physical activity and moderate-to-vigorous physical activity (MVPA) as recorded by the Actigraph 
accelerometer. Other secondary outcomes collected using participant questionnaires and objective 
measures include: (1) indicative change in WC and BMI, (2) indicative change in fatigue, sleep and QOL, (3) 
indicative change in grip strength. 
 
Sample size 
The aim of the present study is to pilot the proposed intervention and if promise is observed we plan to 
secure further funding to incorporate the intervention booklet into a mobile application that we will 
subsequently run a fully powered RCT. As in this scenario we are predominantly interested in “promise” we 
will recruit and trial the intervention in a sample of 30 participants (15 in the control arm and 15 in the 
intervention arm). It should be noted here that findings from this pilot will be used to inform the power 
calculation for the full trial. 
 
Data analysis-Quantitative 
We will summarize all data by treatment group. Statistical measures of central tendency and dispersion such 
as mean, standard deviation (continuous variables), frequency distribution, interquartile range (IQR) and 
median (categorical variables) will be used in descriptive statistics. Non-parametric statistical methods will 
be used for bivariate analysis. Stata version 16 software will be used to perform the analysis. 3.10. Data 
analysis-qualitative 
 
Content analysis will be the first analysis method used but where possible other thematic analysis such as 
Framework analysis or Interpretative Phenomenological Analysis may also be conducted to fit study 
objectives. QSR Nvivo software will be used for data management. 
 
 
Patient and public involvement 
The exercise intervention was developed through an iterative process and consultation with input from 
patients, health professionals (urologists, oncology physiotherapist, personal trainers) and experts 
(academics) in the field. Moreover, this study will interview patients on study exit to further precise the 
intervention. 
 
Ethical considerations and dissemination 
Explicit written informed consent will be sought from all study participants. All participants will be informed 
that they have the right to withdraw from the programme at any point without giving reason. The results of 
this evaluation will be disseminated to academic audiences through presentations at national and 
international conferences in physical activity, public health and medicine and through peerreviewed 
publications in relevant journals. Results will be disseminated to the public, policy makers, and other charities 
through seminars and press releases co-ordinated through the Anglia Ruskin University Press Office. Ethical 




The present protocol is to pilot a home-based exercise intervention co-created through an iterative process 
and tailored specifically for bladder cancer survivors to improve physical and mental health outcomes in this 
population. If the intervention shows promise we will subsequently incorporate the intervention booklet into 
a mobile application and run a fully powered RCT. 
 
A clear strength of this study will be the utilisation of a home-based exercise intervention tailored specifically 
for bladder cancer survivors to promote physical activity and implementing the intervention from the point of 
diagnosis (approximately one week after). However, some limitations may exist. First, owing to the “high-
risk” population we may experience a high level of drop out or a low uptake. It is possible that as someone 
goes through bladder cancer treatment taking up physical activity may not be a priority for them. Second, 
the Actigraph GT3X are calibrated to record ambulatory activity (hip movement) and therefore underestimate 
the intensity of some activities. Third, bladder cancer is most common among older adults who also have a 
high prevalence of multiple non-communicable diseases which may further impact their ability to engage in 
a home-based exercise program [24]. 
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